SUNNYVALE, Calif., March 12, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that Joseph Buggy PhD, Vice President of Research, will be presenting at the ROTH Capital 22nd Annual OC Growth Conference in Dana Point, CA at the Ritz Carlton on Monday, March 15 at 3:00 P.M. PT/6:00 P.M. ET.
There will be a live webcast of the presentation, which will be accessible through a link posted on the investor relations/events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm
Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325
SOURCE Pharmacyclics, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved